Search Results 611-620 of 17373 for bisphosphonates side effects

  1. Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV) - Mayo Clinic

    ... side effects, optimal dosages and risks/benefits. ... Radiotherapy, bisphosphonate, or a single short ... Discontinuation of daratumumab due to a daratumumab- ...

  2. Mayo Clinic Health Letter: Highlights from the March 2015 Issue

    ... side effects. Other options include: MEDIA CONTACT: Brian Kilen, Mayo Clinic Public Affairs, 507-284-5005, newsbureau@mayo.edu. Antidepressant drugs ― These ...

  3. My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors - Mayo Clinic

    ... side effects, optimal dosages and risks/benefits. ... Adverse Events (NCI CTCAE) Grade less than or ... Bisphosphonates and denosumab are allowed; Most ...

  4. Hematology - Clinical trials

    This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in ...

  5. Effects of Aprepitant on Satiation, Gastric Volume, Gastric Accommodation and Gastric Emptying - Mayo Clinic

    ... side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current ...

  6. A Study of Lenvatinib for Treating Patients with Metastatic or Advanced Pheochromocytoma or Paraganglioma that Cannot be Removed by Surgery - Mayo Clinic

    ... side effects, optimal dosages and risks/benefits. ... Negative pregnancy test done ≤ 7 days prior to ... bisphosphonates (e.g. zoledronic acid) or ...

  7. Surgery - Clinical trials

    This phase Ib trial studies the side effects and best dose of a vaccine called H2NVAC before surgery in treating patients with HER2 expressing ductal carcinoma ...

  8. A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency - Mayo Clinic

    ... side effects, optimal dosages and risks/benefits. ... Initiated low-dose corticosteroid, bisphosphonate, or denosumab therapy or adjusted low-dose corticosteroid, ...

  9. Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors - Mayo Clinic

    ... side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current ...

  10. A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer - Mayo Clinic

    ... side effects, optimal dosages and risks/benefits. ... This phase II, single-arm study was designed to evaluate the effect ... bisphosphonate therapy or denosumab ...